Actors | Interests | Actions | Incentives | Disincentives |
---|---|---|---|---|
# 1 Research-based pharmaceutical companies | - Increase turnover, reduce costs; - Strategic interests (e.g. “stay ahead of the curve); - Reputation concerns; - Preserve effectiveness of product by curbing antibiotic resistance. | -Motivate #3: demand good pollution control for the API’s they buy; - Monitor & reduce their own discharges; - Set internal discharge limits; - Act transparently with regards to production sites (also of suppliers) and environmental performance. | - Emission standards; - Legal requirements; - Economic incentives (price, costs, turnover); - Pressure from investors and buyers; - Reputation concerns. | - Transparency as a threat for reputation concerns; - Higher production cost; - Lack of follow-up of external demands - risks of unfair competition. |
#2 Generic pharmaceutical companies | - Increase turnover, reduce costs; - Strategic interests (e.g. “stay ahead of the curve”); - Preserve effectiveness of product by curbing antibiotic resistance. | -Motivate #3: demand good pollution control for the API’s they buy; - Monitor & reduce their own discharges; - Set internal discharge limits; - Act transparently with regards to production sites (also of suppliers) and environmental performance. | - Emission standards; - Legal requirements; - Economic incentives (price, costs, turnover); - Pressure from investors and buyers. | - Higher production cost; - Lack of follow-up of external demands - risks of unfair competition; |
# 3 Subcontracting pharmaceutical companies | - Increase turnover, reduce costs; - Strategic interests (e.g. “stay ahead of the curve”); - Preserve effectiveness of product by curbing antibiotic resistance. | - Monitor and reduce their own discharges; - Set internal discharge limits; - Act transparently with regards to environmental performance. | - Emission standards; - Legal requirements; - Economic incentives (price, costs, turnover); - Pressure from investors and buyers (i.e. #1 & #2). | - Higher production cost; - Lack of follow-up of external demands - risks of unfair competition; |
# 4 Umbrella organisations/ collaborations between pharmaceutical companies. | - Represent members (#1, #2, #3); - Align interests of members. | -Coordinate action | - In addition to those applying to #1,2 and 3: become a stronger force for promoting common interests. | - Interest and priorities may differ between members. |
#5 Owners of pharmaceutical companies | - Profit on investment; - Reputation concerns. | - (Threaten to) withdraw investments in #1, #2 and #3; - Power through representation in boards. | - Pressure from customers and interest groups; - Financial incentives (risk for loss of business associated with “scandals”). | - Limits on (short-term) profits, as owners set profit expectations. |
# 6 Waste water treatment plants (WWTPs) | - Increase turnover, reduce costs. | - Implement more effective treatment; - Monitor and report emissions. | - Government legislation; - Subsidies. | - Costs. |
# 7 Parallel importers | - Increase turnover, reduce costs. | - Promote transparency and regulations. | - Pressure from buyers; - Legislation. | - Very limited ability to gain information on, or to influence the production chain |
# 8 Producing country states | - Represent population; - Protect public health; - Protect economic interests. | -Regulate industry in terms of emissions; -Pressure, negotiate with #1–3; - Sponsor research and knowledge transfer; - Support infrastructure. | - Political pressure from citizens and interest groups; - Treaties, multilateral agreements, foreign pressure; - Public health concerns. | - Economic interests: protecting current industry - strict standards may create disadvantages for national producers; - Lobbying by #1–3. |
# 9 Environmental oversight agencies | - Follow statutes and directives as defined by #8; - Protect the environment (and public health) | - Implement and enforce rules and regulations; -Provide data on emissions. | - Pressure from various actors; - Directives deriving from #8. | - Pressure from #1–3, in particular on the local level. |
# 10 Citizens of producer states | - Economic concerns; - Public health;- environmental protection. | -Pressure industry and government; -Vote. | - Awareness; - Economic, health and environmental interests. | - Lack of information/ awareness; - Lack of interest; - Lack of effective political power. |
# 11 Citizen interest groups, environmental and human rights NGOs. | - Represent #10; - Represent particular interests. | - Coordinate action; - Create awareness; - Exert pressure. | - Pressure from supporters; - ‘Mediagenic’ action may be more attractive with an eye on public support. | - Limited political power. |
# 12 Inter-governmental political forums (eg. G7) | - Coordinate and represent national and international interests. | - Apply political pressure; - Harmonize policies. | - Input by goverments, political leaders; - Pressure by interest groups, political organisations etc. | - Many different interests, they may not always align. |
# 13 United Nations agencies | - Initiate and harmonize collective action on global problems. | - Create awareness; - Harmonize policies across nations; - Exert pressure on industry and governments. | - Pressure from governments, interest groups, political organisations etc. | - Limited power. |
#14 Consumer country states | - Represent population; - Protect public health; - Protect economic interests. | - Regulate; - Establish premiums; - Direct research funding; - Direct actions by national agencies; -Influence other consumer states and # 30. | - Political pressure by citizens and interest groups; - Treaties, multilateral agreements, foreign pressure; - (Global) public health. Concerns. | - Economic interests: costs - Lobbying by #1–3; - Little mass, individually (higher cost to establishing premiums); - Institutional barriers (eg. state generic substitution system). |
# 15 National Licensing agencies (Läkemedelsverket, LV) | - Follow statutes and directives as defined by #14; - Good, affordable health care. | - Implement standards and licensing of medical products; | - Steering by national government. | - Limited mandate. |
# 16 Agencies committed to subsidizing decisions (Tand- och läkemedelsfömånsverket, TLV) | - Follow statutes and directives as defined by #14; - Good, affordable health care. - Effective resource allocation. | Potentially (but not currently): - Weigh environmental concerns in reimbursement decisions. | - Steering by national government. | - Limited mandate; - Limited possibilities for action under current statutes. |
# 17 Agencies committed to prescription policies (Socialstyrelsen, SoS, and Inspektionen för vård och omsorg, IVO | - Follow statutes and directives as defined by #14; - Good, affordable health care. | - Issue national treatment guidelines (in cooperation with # 18). | - Steering by national government. | - Limited mandate. |
#18 Public health agencies | - Follow statutes and directives as defined by #14; - Good, affordable health care. | - Issue national treatment guidelines (in cooperation with # 17) | - Steering by national government. | - Limited mandate. |
#19 Agencies committed to public procurement: Upphandlingsmyndigheten | - Follow statutes and directives as defined by #14; - Good, affordable health care. | - Supporting #20, 21 and 22 to put pressure on # 1 and 2 | - Steering by national government. | - Limited power. |
#20 Public hospitals and clinics | - Follow statutes and directives as defined by #14 and #21; - Represent interests of #26 & #28; - Effective resource allocation. | - Apply environmental criteria in procurement; - Improve awareness. | - Regulation. | - Pressure on cost-efficiency; - Limited negotiating power. |
#21 Regional government (county council) and their regional medical products committees (Läkemedels-kommittér) | - Represent population; - Protect public health; - Good, affordable health care; - Protect economic interests. | - Steer #20; - Weigh in environmental concerns in regional treatment recommendations. | - Political pressure by citizens and interest groups; - National policies; - Public health concerns. | - Limited power. |
#22 Central priority setting organisation for drug procurement (NT-rådet & Sveriges kommuner och landsting, SKL) | - Effective resource allocation; - Good, affordable health care. | - Help counties act jointly and effectively. | - Steering by national government. | - Limited mandate. |
#23 Privately funded and operated clinics and hospitals | - Profit; - Promote and protect health of their patients. | -Apply environmental criteria when buying antibiotics. | - Demands made by subcontracting county councils; - Pressure from #28, 29. | - Very little negotiating power. |
#24 Pharmacies | - Profit; - Reputation concerns. | - Take environmental concerns into account when purchasing antibiotics (applicable to some countries, not all); - Improve awareness. | - Media attention; - Attracting costumers. | -Little or no influence over what antibiotics to provide through governmental restrictions (in some countries, but not all). |
#25 Insurance companies | - Profit; - Reputation concerns. | - Negotiate, pressure # 1,2. | - Financial considerations (e. g. premiums, or taxes). | - Interest in lower prices. |
#26 Physicians and other health care professionals | - Economic interests (in some settings); - Professional ethos. | - Pressure, primarily through #27. | - Increased awareness. -Pressure from lobby groups, particularly #1,2 and 4 (in some settings) | Lack of information/ awareness - Lack of interest/time; - Lack of effective political power. |
#27 Physician and other health care professional organisations | Represent interests of #26. | - Pressure relevant policy makers and institutions. - Create awareness among members, the public, politicians and policy makers. | - Pressure by members. | - Lack of effective political power. |
#28 Patients/ citizens of consumer country states | - Keep costs for medicines low; - Access to antibiotics. | - Support NGO’s; - Vote, exert political pressure; - (When possible) buying “environmentally certified” antibiotics. | - Awareness. | - Lack of information/ awareness; - Lack of interest; -Increased costs for medicines; - Lack of effective political power. |
#29 Patient organisations | Represent interests of #28. | - Pressure on county governments or inter-regional coordinating bodies; - Improve awareness. | - Pressure by members; | - Lack of effective political power. |
#30 Multinational governing bodies (e.g. the EU) | - Represent member states; - Streamlining the national policies. | - Regulate; - Negotiate, pressure; -Subsidize sustainable practices; -Research funding. | - Political pressure; - Treaties, multilateral agreements, foreign pressure. | - Non-aligning interests between member states; - Lobbying; - Lack of jurisdiction. Outside of e.g. EU. |
#31 Agencies of multistate bodies (such as the European Medicines Agency) | - Follow statutes and directives as defined by #14. | - Amend licensing requirements (ERA) to include risks for AMR selection and production emissions; - Include environmental considerations in GMP; - facilitate transparency of production chains. | - Steering by #30. | - Lack of research data to define demands; - Lack of jurisdiction outside of e.g. EU. |
#32 Media | - Profit; - Credibility; - Public interest. | - Improve awareness; - Expose polluters; - Demand action from the majority of actors. | - More viewers/readers; - Curiosity; - Increased credibility. | - Opacity of productions chains; -Lack of emission data. |
# 33 Scientific researchers and universities | - Reputation; - Receive funding. | - Generate knowledge; - Educate and create awareness among other actors; - Propose scientifically funded actions for e.g. regulation and procurement. | - Curiosity - Reputation; - Funding; | - Institutional barriers to multidisciplinary and/or international cooperation; - Limited access to data and samples from industry. |